KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $387,727 | -39.5% | 57,356 | +29.9% | 0.02% | -26.7% |
| Q3 2022 | $641,000 | -18.1% | 44,166 | -44.4% | 0.03% | -6.2% |
| Q2 2022 | $783,000 | -12.1% | 79,499 | +31.6% | 0.03% | -3.0% |
| Q1 2022 | $891,000 | +42.1% | 60,399 | +27.4% | 0.03% | +50.0% |
| Q4 2021 | $627,000 | +2.6% | 47,399 | +35.4% | 0.02% | -15.4% |
| Q3 2021 | $611,000 | -43.3% | 34,999 | -22.2% | 0.03% | -40.9% |
| Q2 2021 | $1,078,000 | -54.8% | 44,999 | -51.5% | 0.04% | -55.1% |
| Q1 2021 | $2,387,000 | +790.7% | 92,863 | +557.3% | 0.10% | +880.0% |
| Q4 2020 | $268,000 | – | 14,129 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |